Larynx Preservation Clinical Trial Design: Key Issues and Recommendations-A Consensus Panel Summary

International Journal of Radiation Oncology Biology Physics

Volumn 73, Issue 5, 2009, Pages 1293-1303

  Lefebvre, Jean Louis ^a   Ang, K Kian ^b  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Guidelines; Head and neck carcinoma; Hypopharyngeal carcinoma; Laryngeal carcinoma; Larynx preservation

Indexed keywords

GUIDELINES; HEAD AND NECK CARCINOMA; HYPOPHARYNGEAL CARCINOMA; LARYNGEAL CARCINOMA; LARYNX PRESERVATION;

FEEDING;

AMPHIREGULIN; BETA CATENIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIREGULIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; PROTEIN P53; UVOMORULIN;

ARTICLE; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CONVALESCENCE; EVENT FREE SURVIVAL; FEEDING APPARATUS; FUNCTIONAL ASSESSMENT; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HEAD CANCER; HUMAN; HYPOPHARYNX CARCINOMA; LARYNGECTOMY; LARYNX; LARYNX CANCER; LARYNX CARCINOMA; LARYNX PRESERVATION; MEDICAL RECORD REVIEW; METHODOLOGY; ORGAN PRESERVATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POPULATION SIZE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SPEECH; SQUAMOUS CELL CARCINOMA; SURGICAL RISK; SWALLOWING; TRACHEOTOMY; TREATMENT DURATION; TREATMENT OUTCOME; VOICE;

AGE FACTORS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS, PHASE III AS TOPIC; COMBINED MODALITY THERAPY; DEGLUTITION DISORDERS; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; LARYNGECTOMY; LARYNX; LYMPHATIC METASTASIS; NEOPLASM STAGING; PATIENT SELECTION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; RISK ASSESSMENT; TRACHEOTOMY;

EID: 62649090804     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.047     Document Type: Article

References (47)

1. VALCSG (The Department of Veterans Affairs Laryngeal Cancer Study Group). Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324 (1991) 1685-1690
2. Lefebvre J.-L., Chevalier D., Luboinski B., et al. Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88 (1996) 890-899
3. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349 (2003) 2091-2098
4. Forastiere A.A., Maor M., Weber R.S., et al. Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy vs. concurrent cisplatin and radiation therapy vs. radiation therapy. [ASCO Annual Meeting Proc Part I, abstract]. J Clin Oncol 2006 24 Suppl (2006) 5517
5. Marur S., and Forastiere A.A. Head and neck cancer: Changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83 (2008) 489-501
6. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357 (2007) 1705-1715
7. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
8. Urba S., Wolf G., Eisbruch A., et al. Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 24 (2006) 593-598
9. Weber R.S., Berkey B.A., Forastiere A., et al. Outcome of salvage total laryngectomy following organ preservation therapy: The Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg 129 (2003) 44-49
10. Spaulding M.B., Fischer S.G., Wolf G.T., et al. Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma. J Clin Oncol 12 (1994) 1592-1599
11. Bradford C.R., Wolf G.T., Carey T.E., et al. Predictive markers for response to chemotherapy, organ preservation, and survival in patients with advanced laryngeal carcinoma. Otolaryngol Head Neck Surg 121 (1999) 534-538
12. Lefebvre J.-L., Chevalier D., Luboinski B., et al. Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the EORTC 24891 trial. [ASCO Annual Meeting Proc (Post-Meeting Edition, abstract]. J Clin Oncol 22 Suppl (2004) 5531
13. Richard J.M., Sancho-Garnier H., Pessey J.J., et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 34 (1998) 224-228
14. Calais G., Pointreau Y., Alfonsi M., et al. Induction chemotherapy for larynx preservation. Updated results of the GORTEC 2000-01 randomized trial comparing docetaxel + cisplatinum + fluorouracil (TPF) vs. cisplatinum + fluorouracil (PF). [Abstract]. Eur J Cancer 5 Suppl (2007) 324
15. Lefebvre J., Horiot J., Rolland F., et al. Phase III study on larynx preservation comparing induction chemotherapy and radiotherapy vs. alternating chemoradiotherapy in resectable hypopharynx and larynx cancers. EORTC protocol 24954-22950. [ASCO Annual Meeting Proc Part I, abstract]. J Clin Oncol 25 Suppl (2007) LBA6016
16. Bernier J., Cooper J.S., Pajak T.F., et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 27 (2005) 843-850
17. Brockstein B., Haraf D.J., Rademaker A.W., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol 15 (2004) 1179-1186
18. Li X.M., Wei W.I., Guo X.F., et al. Cervical lymph node metastatic patterns of squamous carcinomas of the upper aerodigestive tract. J Laryngol Otol 110 (1996) 937-941
19. Mendenhall W.M., Parsons J.T., Stringer S.P., et al. Stage T3 squamous cell carcinoma of the glottic larynx: A comparison of laryngectomy and irradiation. Int J Radiat Oncol Biol Phys 23 (1992) 725-732
20. MacKenzie R., Franssen E., Balogh J., et al. The prognostic significance of tracheostomy in carcinoma of the larynx treated with radiotherapy and surgery for salvage. Int J Radiation Oncology Biol Phys 41 (1998) 43-51
21. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 355 (2000) 949-955
22. Lefebvre J.-L., Buisett E., Coche-Dequeant B., et al. Epilarynx: Pharynx or larynx?. Head Neck 17 (1995) 377-781
23. Eisbruch A., Thornton A.F., Urba S., et al. Chemotherapy followed by accelerated fractionated radiation for larynx preservation in patients with advanced laryngeal cancer. J Clin Oncol 14 (1996) 2322-2330
24. Machtay M., Moughan J., Trotti A., et al. Pre-treatment and treatment related risk factors for severe late toxicity after chemo-RT for head and neck cancer: An RTOG analysis. [ASCO Annual Meeting Proc Part I, abstract]. J Clin Oncol 24 Suppl (2006) 5500
25. Rosen C.A., Lee A.S., Osborne J., et al. Development and validation of the voice handicap index-10. Laryngoscope 114 (2004) 1549-1556
26. Hogikyan N.D., and Sethuraman G. Validation of an instrument to measure voice-related quality of life (V-RQOL). J Voice 13 (1999) 557-569
27. Fung K., Lyden T.H., Lee J., et al. Voice and swallowing outcomes of an organ-preservation trial for advanced laryngeal cancer. Int J Radiat Oncol Biol Phys 63 (2005) 1395-1399
28. List M.A., Rutherford J.L., Stracks J., et al. Prioritizing treatment outcomes: Head and neck cancer patients vs. nonpatients. Head Neck 26 (2004) 163-170
29. Ronis D.L., Duffy S.A., Fowler K.E., et al. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 134 (2008) 241-248
30. Terrell J.E., Ronis D.L., Fowler K.E., et al. Clinical predictors of quality of life in patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 130 (2004) 401-408
31. Hoffman H.T., Porter K., Karnell L.H., et al. Laryngeal cancer in the United States: Changes in demographics, patterns of care, and survival. Laryngoscope 116 Suppl 111 (2006) 1-13
32. Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
33. Ang K.K., Berkey B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
34. Sok J.C., Coppelli F.M., Thomas S.M., et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 12 (2006) 5064-5073
35. Mountzios G., Handra-Luca A., Hernandez J., et al. ERCC1 immunohistochemical expression and cancer-specific survival in patients with locally advanced squamous-cell carcinoma of the head and neck treated by cisplatin-based induction chemotherapy. [ASCO Annual Meeting Proc Part I, abstract]. J Clin Oncol 25 Suppl (2007) 6011
36. El-Naggar A.K., Lippman S.M., Johnson F.M., et al. Correlation of Src activation with epithelial-mesenchymal transformation and aggressive features of head and neck squamous carcinoma. [ASCO Annual Meeting Proc Part I, abstract]. J Clin Oncol 25 Suppl (2007) 6026
37. Khambata-Ford S., Garrett C.R., Meropol N.J., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25 (2007) 3230-3237
38. Poeta M.L., Manola J., Goldwasser M.A., et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N Engl J Med 357 (2007) 2552-2561
39. Rosenbek J.C., Robbins J.A., Roecker E.B., et al. A penetration-aspiration scale. Dysphagia 11 (1996) 93-98
40. Rademaker A.W., and Pauloski B.F. Oropharyngeal swallow efficiency as a representative measure of swallowing function. J Speech Hearing Res 37 (1994) 314-325
41. Ludlow, CL, Sonies, BC, Humbert IA, et al. Validity and reliability of the Swallowing Safety Scale. Poster presentation at The Fifteenth Annual Dysphagia Research Society Meeting, March 8-10, 2007. Poster #59; Conference book p 362.
42. List M.A., Ritter-Sterr C., and Lansky S.B. A performance status scale for head and neck cancer patients. Cancer 66 (1990) 564-569
43. Chen A.Y., Frankowski R., Bishop-Leone J., et al. The development and validation of a dysphagia-specific quality-of-life questionnaire for patients with head and neck cancer: The M.D. Anderson Dysphagia Inventory. Arch Otolaryngol Head Neck Surg 127 (2001) 870-876
44. Karnell M., Melton J., Childes T., et al. Reliability of clinician-based (GRBAS and CAPE-V) and patient-based (V-RQOL and IPVI) documentation of voice disorders. J Voice 21 (2007) 576-590
45. Rosenthal D.I., Mendoza T.R., Chambers M.S., et al. Measuring head and neck cancer symptom burden: The development and validation of the M.D. Anderson Symptom Inventory, head and neck module. Head Neck 29 (2007) 923-931
46. Bjordal K., Hammerlid E., Ahlnder-Elmqvist M., et al. Quality of life in head and neck cancer patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35. J Clin Oncol 17 (1999) 1008-1019
47. Op de Coul B.M., Ackerstaff A.H., van As C.J., et al. Quality of life assessment in laryngectomized individuals: Do we need additions to standard questionnaires in specific clinical research projects?. Clin Otolaryngol 30 (2005) 169-175